| Ionis to present at upcoming investor conferences |
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 U. |
businesswire.com |
2025-02-25 09:05:00 |
Czytaj oryginał (ang.) |
| Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus |
IONS reports better-than-expected top and bottom-line numbers for the fourth quarter. |
zacks.com |
2025-02-20 14:15:30 |
Czytaj oryginał (ang.) |
| New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control |
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organiz. |
businesswire.com |
2025-02-20 09:00:00 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript |
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2024 Earnings Conference Call February 19, 2025 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Kyle Jenne - Chief Global Product Strategy Officer Richard Geary - Chief Development Officer Elizabeth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Development and Operations Officer Conference Call Participants Michael Ulz - Morgan Stanley Jessica Fye - JPMorgan Chase & Co. Akash Tewari - Jefferies Yanan Zhu - Wells Fargo Securities Jay Olson - Oppenheimer & Co. Chi Fong - Bank of America Merrill Lynch Gary Nachman - Raymond James & Associates, Inc. Yaron Werber - TD Cowen Operator Good morning, and welcome to Ionis' Fourth Quarter and Full-Year 2024 Financial Results Conference Call. As a reminder, this call is being recorded. |
seekingalpha.com |
2025-02-19 18:10:24 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval |
Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, but expansion into the larger sHTG market by 2025 is crucial for the company to reach profitability and satisfy analyst's estimates. Ionis has a strong cash position and a robust pipeline of over 40 RNA-targeted therapeutics, making it a compelling watch-list candidate. |
seekingalpha.com |
2025-02-19 16:40:42 |
Czytaj oryginał (ang.) |
| Ionis Pharma Beats Expectations for Q4 |
Ionis Pharmaceuticals (IONS 0.44%), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperformed analysts' top-line expectations with revenue of $227 million compared to the anticipated $135 million. |
fool.com |
2025-02-19 15:26:55 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales |
On Wednesday, Ionis Pharmaceuticals Inc IONS reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the consensus of a $1.10 loss. |
benzinga.com |
2025-02-19 14:11:53 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-19 12:35:39 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates |
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.06 per share a year ago. |
zacks.com |
2025-02-19 11:10:36 |
Czytaj oryginał (ang.) |
| Ionis reports fourth quarter and full year 2024 financial results |
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024. “With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Over the next three years, we expect three more. |
businesswire.com |
2025-02-19 09:00:00 |
Czytaj oryginał (ang.) |
| Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS |
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-02-17 12:21:19 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? |
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-12 13:06:36 |
Czytaj oryginał (ang.) |
| Ionis to hold fourth quarter and full year 2024 financial results webcast |
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that b. |
businesswire.com |
2025-02-05 09:05:00 |
Czytaj oryginał (ang.) |
| Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034 |
The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, increased focus on rare diseases, improved healthcare infrastructure, increased awareness and support programs, and strategic alliances and collaborations. The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, increased focus on rare diseases, improved healthcare infrastructure, increased awareness and support programs, and strategic alliances and collaborations. |
globenewswire.com |
2025-01-15 11:17:00 |
Czytaj oryginał (ang.) |
| Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum |
– Accelerating value creation with numerous commercial, regulatory and pipeline milestones – – Ionis outlines clear path to sustained positive cash flow – CARLSBAD, Calif. , Jan. 13, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones expected in 2025. |
prnewswire.com |
2025-01-13 10:00:00 |
Czytaj oryginał (ang.) |
| Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference |
CARLSBAD, Calif. , Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. |
prnewswire.com |
2025-01-08 18:11:00 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval |
Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza for FCS positions Ionis as the first company to independently develop and launch an RNA-targeted therapy. Ionis forecasts that its pipeline, containing approximately 40 investigational drugs, could generate billions in peak sales, with four launches projected in the next three years. |
seekingalpha.com |
2024-12-23 09:30:00 |
Czytaj oryginał (ang.) |
| Ionis Gets FDA Approval for Rare Disease Drug Tryngolza |
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval. |
zacks.com |
2024-12-20 11:06:19 |
Czytaj oryginał (ang.) |
| FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood |
On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s IONS Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can lead to acute pancreatitis (AP). |
benzinga.com |
2024-12-20 09:24:43 |
Czytaj oryginał (ang.) |
| TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet |
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adults with FCS regardless of genetically or clinically confirmed diagnosis TRYNGOLZA is the first of four independent launches planned over the next three years, pending approvals Ionis to host webcast today at 6:45pm ET CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). |
prnewswire.com |
2024-12-19 20:28:00 |
Czytaj oryginał (ang.) |
| US FDA approves Ionis Pharma's genetic disorder drug |
The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed on Thursday. |
reuters.com |
2024-12-19 19:18:28 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% |
The mean of analysts' price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-12-11 12:55:29 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? |
Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-11-27 15:01:17 |
Czytaj oryginał (ang.) |
| Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks |
Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-11-18 12:37:16 |
Czytaj oryginał (ang.) |
| Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus |
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024. |
zacks.com |
2024-11-07 18:01:13 |
Czytaj oryginał (ang.) |
| Ionis to present at upcoming investor conferences |
CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Guggenheim's Inaugural Healthcare Conference on Wednesday, November 13, 2024 UBS Global Healthcare Conference on Wednesday, November 13, 2024 Stifel 2024 Healthcare Conference on Monday, November 18, 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024 Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. |
prnewswire.com |
2024-11-07 09:05:00 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript |
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia – Chief Executive Officer Eugene Schneider – Chief Clinical Development Officer Kyle Jenne – Chief Global Product Strategy Officer Beth Hougen – Chief Financial Officer Jonathan Birchall – Chief Commercial Officer Eric Swayze – Executive Vice President of Research Richard Geary – Chief Development Officer Conference Call Participants Gary Nachman – Raymond James Jessica Fye – JPMorgan Avi Novick – Morgan Stanley Yanan Zhu – Wells Fargo Securities Luca Issi – RBC David Lebowitz – Citi Jason Gerberry – Bank of America Jay Olson – Oppenheimer Mani Foroohar – Leerink Andy Chen – Wolfe Research Operator Good morning and welcome to the Ionis Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. |
seekingalpha.com |
2024-11-06 16:35:23 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics |
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-06 12:35:37 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates |
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago. |
zacks.com |
2024-11-06 11:10:46 |
Czytaj oryginał (ang.) |
| Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome |
Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study planned for H1 2025 Ionis to share ION582 program update at the FAST Global Science Summit in November CARLSBAD, Calif. , Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and Drug Administration (FDA) on ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS). |
prnewswire.com |
2024-11-06 09:01:00 |
Czytaj oryginał (ang.) |
| Ionis reports third quarter 2024 financial results |
WAINUA TM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif. , Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024. |
prnewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS |
Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024. |
zacks.com |
2024-11-04 12:22:04 |
Czytaj oryginał (ang.) |
| Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE |
Donidalorsen will be a first-in-class RNA-targeted medicine for hereditary angioedema, assuming approval Donidalorsen PDUFA date set for August 21, 2025 Donidalorsen has the potential to be Ionis' second independent commercial launch CARLSBAD, Calif. , Nov. 4, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. |
prnewswire.com |
2024-11-04 11:44:00 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-30 13:06:31 |
Czytaj oryginał (ang.) |
| Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling |
Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved drugs and expects significant revenue growth from upcoming approvals, particularly Wainua in ATTR-CM and Olezarsen in SHTG. Ionis' innovative antisense and siRNA technologies target RNA to treat various diseases, with potential multi-billion dollar peak revenue drugs nearing commercial approval. |
seekingalpha.com |
2024-10-23 20:25:31 |
Czytaj oryginał (ang.) |
| Ionis to hold third quarter 2024 financial results webcast |
Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern Time CARLSBAD, Calif. |
prnewswire.com |
2024-10-23 11:05:00 |
Czytaj oryginał (ang.) |